Jefferies Changes Estimates Raises Price Target on Integra Life-Sciences (IART)

Jefferies analysts raised their price target on Integra Life-Sciences (NASDAQ: IART) from $37 to $40, while maintaining their BUY rating. They also increased EPS estimates 3c for 2012 and 7c for 2013.

Integra is a global leader in neurosciences and has a fast growing orthopedics division which has become the largest business unit for the company. Jefferies analysts view Integra as “well-positioned for sustainable mid-single digit revenue growth and faster earnings growth.”

The $40 target is based on 12x multiple Jefferies 2013 EPS estimate of $3.39 (increased from $3.32).

For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.

Shares of Integra LifeSciences closed at $36.24 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Advance Auto Parts (AAP) PT Lowered to $43 at Truist Securities
• Is the global equity rally broadening? UBS weighs in